| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/CHMP/120218/2012 (16.2.12) |
| Publication Date | 16/02/2012 |
| Content Type | News |
|
Finalising its review on orlistat-containing medicines and the possible risk of severe liver injuries, which began in September 2011, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded, in February 2012, that the benefit of these medicines continue to outweigh their risks in the treatment of obese or overweight patients with a body mass index of 28 kg/m2 or above. |
|
| Source Link | Link to Main Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/02/news_detail_001443.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe |
